Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis
Authors:
- Mattia ZampieriMZMattia Zampieri
- Annamaria Del FrancoAFAnnamaria Del Franco
- Marco CanepaMCMarco Canepa
- Italo PortoIPItalo Porto
- Margherita ZanolettiMZMargherita Zanoletti
- Marianna Eleonora LabateMLMarianna Eleonora Labate
- Aldostefano PorcariAPAldostefano Porcari
- Luca BordignonLBLuca Bordignon
- Marco MerloMMMarco Merlo
- Gianfranco SinagraGSGianfranco Sinagra
- Giacomo TiniGTGiacomo Tini
Open Access
- 1 March 2026
- journal article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (3) , e012337
Abstract
BACKGROUND: The tenet of cardiac amyloidosis (CA) as a paradigm of heart failure with restrictive ventricular physiology and preserved systolic function has come under scrutiny. We aimed to evaluate the prevalence and clinical significance of left ventricular (LV) systolic dysfunction versus restriction in a large real-world cohort with CA, assessed at the time of diagnosis. METHODS: We retrospectively analyzed 540 TTR (transthyretin)-CA and 280 AL (light chain)-CA. Patients were divided into 3 LV phenotypes: (1) preserved LV function: LV ejection fraction >40% associated with grade I diastolic dysfunction; (2) restriction: LV ejection fraction >40% associated with grade II/III diastolic dysfunction; (3) systolic dysfunction: LV ejection fraction ≤40% irrespective of diastolic function. We analyzed the progression from preserved LV function towards the other 2 LV phenotypes and survival free from the composite end point of all-cause mortality and heart transplantation. RESULTS: In TTR-CA, the prevalence of preserved LV function was 32.0%, restriction was 56.1%, and systolic dysfunction was 11.9%. Among patients with preserved LV function, at the last evaluation, the conversion rate to restriction was 16.3% and to systolic dysfunction was 1.8%. The 3-year freedom from the composite end point was 75%, 61%, and 44%, respectively. In AL-CA, the prevalence of preserved LV function was 32.9%, restriction was 58.6%, and systolic dysfunction was 8.5%. Among patients with preserved LV function, at the last evaluation, the conversion rate to restriction was 12.9%, and to systolic dysfunction was none. The 3-year freedom from the composite end point was 46%, 32%, and 21%, respectively. CONCLUSIONS: Restriction was the most common presenting phenotype, while preserved LV function represented approximately one-third. The rate of progression from preserved LV function towards restriction was high, whereas it was limited towards systolic dysfunction. Although patients with preserved LV function presented the best event-free survival, considering all-cause mortality and heart transplantation, compared with restriction or systolic dysfunction, these phenotypes are not independent predictors of this composite end point.Keywords
This publication has 27 references indexed in Scilit:
- The Impact of Patients With Cardiac Amyloidosis in HFpEF TrialsJACC: Heart Failure, 2021
- Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart FailureEuropean Journal of Heart Failure, 2021
- Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatmentAmerican Journal of Hematology, 2020
- Multiparametric Echocardiography Scores for the Diagnosis of Cardiac AmyloidosisJACC: Cardiovascular Imaging, 2020
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilizationJournal of Nuclear Cardiology, 2019
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2016
- Diagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisJACC, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Pseudonormal Mitral Filling Is Associated with Similarly Poor Prognosis as Restrictive Filling in Patients with Heart Failure and Coronary Heart Disease: A Systematic Review and Meta-analysis of Prospective StudiesJournal of the American Society of Echocardiography, 2009
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and AmyloidosisAmerican Journal of Hematology, 2005